ASUS MH Series Clinical Displays Earn Class 1 Device Status from US FDA

ASUS introduces its new line of clinical displays, the MH series, which are FDA Class 1 Devices and feature advanced technology and certifications for accurate and comfortable medical image viewing, with plans for further global compliance and partnerships with medical institutions.

Class 1 Device classification by the US FDA
Compliance with DICOM Part 14 Grayscale Standard Display Function (GSDF) AAPM TG270 standard
Certification for use in clinics and large medical institutions

ASUS, the tech company, has recently launched its latest line of clinical displays under the MH series. What sets these displays apart is their recent classification as Class 1 Devices by the US Food and Drug Administration (FDA), which is a significant achievement for ASUS.

The MH series includes three models: the 32-inch 8-megapixel MH3281A, the 27-inch 4-megapixel MH2741A, and the 23.8-inch MH2441A. These displays are specifically designed for radiology and Picture Archiving and Communication System (PACS) use, making them ideal for medical professionals in these fields.

One of the standout features of these monitors is their compliance with the DICOM Part 14 Grayscale Standard Display Function (GSDF) AAPM TG270 standard. This ensures that the medical images displayed on these monitors are consistent and highly accurate. Additionally, the monitors come equipped with scheduled calibration, dynamic brightness compensation, and dynamic DICOM compensation to further enhance image quality.

To reduce eye strain and provide a more comfortable viewing experience, the monitors feature an anti-glare, low-reflection (AGLR) coating on the panel. ASUS has also put these displays through rigorous performance tests and obtained certification from TÜV Rheinland to guarantee flicker-free performance and low blue light emissions.

In addition to meeting ISO 13485 requirements, these clinical displays have been certified for use in clinics and large medical institutions. ASUS is not stopping at FDA certification; the company is actively seeking CE marks to comply with EU Medical Device Regulation guidelines and approval from the Taiwan Food and Drug Administration (TFDA) for its clinical displays. This demonstrates ASUS’s commitment to providing reliable and high-quality medical devices to a global market.

Furthermore, ASUS is keen on establishing partnerships with major medical institutions worldwide to gain a deeper understanding of industry needs and stay ahead of the ever-evolving medical-device market. By doing so, ASUS aims to offer a range of innovative solutions tailored to the specific requirements of European and Asian markets.

The latest ASUS MH series clinical displays are a testament to the company’s dedication to delivering technology that meets the stringent standards set by regulatory bodies. With their advanced features and certifications, these displays are poised to make a significant impact in the medical field, providing professionals with the tools they need for accurate diagnosis and efficient workflow.

About Our Team

Our team comprises industry insiders with extensive experience in computers, semiconductors, games, and consumer electronics. With decades of collective experience, we’re committed to delivering timely, accurate, and engaging news content to our readers.

Background Information

About ASUS:

ASUS, founded in 1989 by Ted Hsu, M.T. Liao, Wayne Hsieh, and T.H. Tung, has become a multinational tech giant known for its diverse hardware products. Spanning laptops, motherboards, graphics cards, and more, ASUS has gained recognition for its innovation and commitment to high-performance computing solutions. The company has a significant presence in gaming technology, producing popular products that cater to enthusiasts and professionals alike. With a focus on delivering and reliable technology, ASUS maintains its position as a important player in the industry.